title: Prevention of aortocoronary vein bypass graft occlusion: which antithrombotic treatment and for how long?
abstract: The effects of 50 mg aspirin combined with 400 mg dipyridamole were compared with those of standard anticoagulant therapy, in the prevention of aortocoronary vein bypass graft occlusion. Early graft occlusion in 249 patients, with 749 distal vein graft anastomoses, were angiographically assessed 11.5 +/- 2 days after surgery and were almost equal in both treatment groups. In half of the patients in each group, active treatment was replaced by placebo after 3 months. Repeat angiography after 1 year (360 +/- 24 days) showed that more new late graft occlusions occurred in patients with only 3 months active medication (either regimen). The incidence of major complications was significantly higher in patients treated with anticoagulants, with minor side-effects more common in the antiplatelet group. Thus, this antiplatelet drug regimen was as effective as standard anticoagulant therapy in the prevention of early and late bypass graft occlusion, but carried a significantly lower risk of severe complications. In addition, as replacement of active treatment by placebo after 3 months resulted in significantly more graft occlusions, antithrombotic treatment should be continued for at least one year after coronary artery bypass graft surgery.
authors.affiliation: Division of Cardiology, Angiography, University Hospital Basel, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Pfisterer
authors.forename: F
authors.initials: F
authors.lastname: Burkart
authors.forename: G
authors.initials: G
authors.lastname: Jockers
authors.forename: B
authors.initials: B
authors.lastname: Meyer
authors.forename: S
authors.initials: S
authors.lastname: Regenass
authors.forename: D
authors.initials: D
authors.lastname: Burckhardt
authors.forename: H E
authors.initials: HE
authors.lastname: Schmitt
authors.forename: J
authors.initials: J
authors.lastname: Müller-Brand
authors.forename: K
authors.initials: K
authors.lastname: Skarvan
authors.forename: P
authors.initials: P
authors.lastname: Stulz
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D004176:Dipyridamole; D001241:Aspirin